ReviewNature protocols2026
A generic, rapid and robust platform for personalized functional circuit-guided neuromodulation targeting.
Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Excessive Censoring Degrades Individual-Specific Cortical Parcellations and Personalized TMS Targets.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromodulation approaches can target specific brain functional circuits to treat various brain disorders, and resting-state functional magnetic resonance imaging is increasingly being used to map functional circuits in individual patients for target localization. However, this strategy faces three major hurdles for clinical translation: time-intensive resting-state functional magnetic resonance imaging processing, insufficient robustness for clinical use and a lack of automated targeting solutions. Here we cover the use of a generic, rapid, robust and automated platform for personalized functional circuit-guided target planning across different neuromodulation techniques, termed Unified Platform for Neuromodulation with Individualized Target Estimation (UNITE). UNITE is computationally efficiency and robust and uses DeepPrep, a recently developed end-to-end preprocessing pipeline that achieves a tenfold speedup and improved robustness compared with state-of-the-art clinical pipeline. Using DeepPrep's preprocessed data, UNITE maps functional circuits and localizes personalized targets through automated targeting algorithms. Currently, UNITE offers three built-in transcranial magnetic stimulation-targeting algorithms for post-stroke functional rehabilitation and one focused ultrasound stimulation-targeting algorithm for Parkinson's disease. Notably, it is designed to be adapted for other brain disorders and neuromodulation applications. To ensure quality and usability, UNITE generates a data quality control report and a visual verification report of the identified targets, with target coordinates exported in multiple formats for compatibility with different neuronavigation systems. Overall, this platform enables personalized neuromodulation target localization within 30 min on a local graphics processing unit-equipped workstation. A basic level of computer science proficiency, along with neuroimaging experience, is sufficient for its use.
Identifiers
42204340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.